Literature DB >> 15716330

Role of ERK1/2 and p38 mitogen-activated protein kinases in the regulation of thrombospondin-1 by TGF-beta1 in rat proximal tubular cells and mouse fibroblasts.

Takahiko Nakagawa1, Hui Y Lan, Olena Glushakova, Hong J Zhu, Duk-Hee Kang, George F Schreiner, Erwin P Böttinger, Richard J Johnson, Yuri Y Sautin.   

Abstract

Thrombospondin-1 (TSP-1) inhibits angiogenesis and activates latent TGF-beta1, both of which are strongly associated with progression of renal disease. Recently, it was reported that Smad2 but not Smad3 regulates TSP-1 expression in response to TGF-beta1 in rat tubular epithelial cells as well as in mouse fibroblasts. This study investigated the role of ERK1/2 and p38 mitogen-activated protein kinases (MAPK). TGF-beta1 activated both ERK1/2 and p38 in the rat proximal tubular cell line NRK52E. Blocking ERK1/2 and p38 inhibited TGF-beta1-induced TSP-1 mRNA and protein expression. Next, the cross-talk between Smad2 and ERK1/2 or p38 was examined. Whereas blocking of ERK1/2 or p38 failed to inhibit TGF-beta1-induced Smad2 activation, inhibition of Smad2 by Smad7 overexpression inhibited the phosphorylation of ERK1/2 but not p38 in response to TGF-beta1. Similar results were observed using mouse fibroblasts from Smad2 knockout embryos, in that TGF-beta1 was able to activate p38 but not ERK1/2 in this cell line. In conclusion, TSP-1 expression is regulated by both ERK1/2 and p38 MAPK in rat proximal tubular cells and mouse fibroblasts in response to TGF-beta1. The ERK1/2 activation is dependent on Smad2 activation, whereas the p38 activation occurs independent of Smad2. Because TSP-1 is a major antiangiogenic molecule and an activator of TGF-beta1, this provides an important insight to the mechanism by which TGF-beta1 may mediate interstitial fibrosis and progressive renal disease.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15716330     DOI: 10.1681/ASN.2004080689

Source DB:  PubMed          Journal:  J Am Soc Nephrol        ISSN: 1046-6673            Impact factor:   10.121


  29 in total

1.  Isogenic mesenchymal stem cells transplantation improves a rat model of chronic aristolochic acid nephropathy via upregulation of hepatic growth factor and downregulation of transforming growth factor β1.

Authors:  Wei Li; Hong Jiang; Jiang-Min Feng
Journal:  Mol Cell Biochem       Date:  2012-06-04       Impact factor: 3.396

2.  Erbin inhibits TGF-β1-induced EMT in renal tubular epithelial cells through an ERK-dependent pathway.

Authors:  Qiaodan Zhou; Rui Zeng; Chuou Xu; Lili Liu; Lin Chen; Pei Kou; Guangchang Pei; Shoujun Bai; Yamin Zhang; Caixia Li; Song Rong; Min Han; Gang Xu
Journal:  J Mol Med (Berl)       Date:  2011-11-25       Impact factor: 4.599

3.  Purinergic signaling induces thrombospondin-1 expression in astrocytes.

Authors:  Minh D Tran; Joseph T Neary
Journal:  Proc Natl Acad Sci U S A       Date:  2006-06-05       Impact factor: 11.205

4.  miR-29b as a therapeutic agent for angiotensin II-induced cardiac fibrosis by targeting TGF-β/Smad3 signaling.

Authors:  Yang Zhang; Xiao-Ru Huang; Li-Hua Wei; Arthur Ck Chung; Cheuk-Man Yu; Hui-Yao Lan
Journal:  Mol Ther       Date:  2014-02-26       Impact factor: 11.454

5.  Morphine modulation of thrombospondin levels in astrocytes and its implications for neurite outgrowth and synapse formation.

Authors:  Hiroko Ikeda; Mayumi Miyatake; Noriaki Koshikawa; Kuniyasu Ochiai; Kiyoshi Yamada; Alexi Kiss; Maureen J Donlin; W Michael Panneton; James D Churchill; Michael Green; Akbar M Siddiqui; Andrew L Leinweber; Nicholas R Crews; Lubov A Ezerskiy; Victoria R Rendell; Mariana M Belcheva; Carmine J Coscia
Journal:  J Biol Chem       Date:  2010-10-02       Impact factor: 5.157

6.  Constitutively activated dystrophic muscle fibroblasts show a paradoxical response to TGF-beta and CTGF/CCN2.

Authors:  Valeria Mezzano; Daniel Cabrera; Cecilia Vial; Enrique Brandan
Journal:  J Cell Commun Signal       Date:  2008-04-15       Impact factor: 5.782

7.  A thrombospondin-1 antagonist of transforming growth factor-beta activation blocks cardiomyopathy in rats with diabetes and elevated angiotensin II.

Authors:  Souad Belmadani; Juan Bernal; Chih-Chang Wei; Manuel A Pallero; Louis Dell'italia; Joanne E Murphy-Ullrich; Kathleen H Berecek
Journal:  Am J Pathol       Date:  2007-07-19       Impact factor: 4.307

8.  Lowering blood pressure blocks mesangiolysis and mesangial nodules, but not tubulointerstitial injury, in diabetic eNOS knockout mice.

Authors:  Tomoki Kosugi; Marcelo Heinig; Takahiro Nakayama; Thomas Connor; Yukio Yuzawa; Qiuhong Li; William W Hauswirth; Maria B Grant; Byron P Croker; Martha Campbell-Thompson; Li Zhang; Mark A Atkinson; Mark S Segal; Takahiko Nakagawa
Journal:  Am J Pathol       Date:  2009-02-26       Impact factor: 4.307

9.  Growth compensatory role of sulindac sulfide-induced thrombospondin-1 linked with ERK1/2 and RhoA GTPase signaling pathways.

Authors:  Yuseok Moon; Jeung Il Kim; Hyun Yang; Thomas E Eling
Journal:  Life Sci       Date:  2007-12-23       Impact factor: 5.037

10.  Chronic Hyperglycaemia Induced Alterations of Hepatic Stellate Cells Differ from the Effect of TGFB1, and Point toward Metabolic Stress.

Authors:  Katalin Kiss; Eszter Regős; Kristóf Rada; Gábor Firneisz; Kornélia Baghy; Ilona Kovalszky
Journal:  Pathol Oncol Res       Date:  2018-08-14       Impact factor: 3.201

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.